Bioabsorbable Stent Coating Molecular Weight Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current drug-eluting stents face challenges with compromised coating integrity due to ethylene oxide sterilization and crimping processes, leading to issues like polymer deformation and adhesion to delivery balloons, as well as suboptimal mechanical properties and prolonged absorption periods of aliphatic polyesters like PLLA.

Innovation Solution

A bioabsorbable stent coating comprising a D,L-PLA polymer with a number average molecular weight below 60,000 Daltons, a thickness of less than 5 micrometers, and a primer layer of high molecular weight polymer, which completely absorbs within 3 to 6 months, along with the option of lactide monomers and oligomers, and a bioactive agent like novolimus.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If a completely amorphous bioabsorbable polymer is used for coating a stent, then the coating can be applied, but the coating integrity is compromised during ETO sterilization or crimping due to polymer deformation and adhesion

Engineering Contradiction:
Improvecoating applicationVSAvoidcoating integrity
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the molecular weight parameter of the D,L-PLA polymer to below 60,000 Daltons and controls the coating thickness to less than 5 micrometers. These parameter changes modify the polymer's physical properties to reduce deformation and adhesion during sterilization and crimping while maintaining coating integrity.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite coating system combining D,L-PLA polymer with novolimus drug, where the polymer matrix provides structural integrity and the drug reservoir provides therapeutic function. This composite approach allows the coating to maintain integrity during processing while delivering drug benefits.

Inventive Principle:
Principle #40Composite materials

2Object-affected harmful factors

If PLLA is used as the polymer material, then the coating is biodegradable and biocompatible, but the mechanical properties are compromised after fabrication and deployment

Engineering Contradiction:
ImprovebiocompatibilityVSAvoidmechanical properties
Core Design Contradiction:
Object-affected harmful factorsVSStrength

Solution Approach 1:

The patent changes the molecular weight parameter of the D,L-PLA polymer to below 60,000 Daltons, which modifies the mechanical properties by reducing brittleness and improving flexibility while maintaining biodegradability and biocompatibility of the PLLA material.

Inventive Principle:
Principle #35Parameter changes

3Duration of action of stationary object

If PLLA is used as the polymer material, then the coating is biodegradable, but the absorption period is relatively long

Engineering Contradiction:
ImprovebiodegradabilityVSAvoidabsorption period
Core Design Contradiction:
Duration of action of stationary objectVSLoss of time

Solution Approach 1:

The patent changes the molecular weight parameter of the D,L-PLA polymer to below 60,000 Daltons, which accelerates the hydrolysis and degradation rate of the polymer, thereby reducing the absorption period from several months to 3-6 months while maintaining complete biodegradability.

Inventive Principle:
Principle #35Parameter changes

4Productivity

If the coating thickness is reduced to improve drug delivery, then the drug delivery efficiency increases, but the coating becomes more susceptible to damage during processing

Engineering Contradiction:
Improvedrug delivery efficiencyVSAvoidcoating integrity
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent optimizes the coating thickness parameter to less than 5 micrometers, which is thin enough to allow efficient drug diffusion and delivery while being thick enough to maintain structural integrity during ETO sterilization and crimping processes when combined with the low molecular weight D,L-PLA polymer.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The coating provides enhanced mechanical properties and reduced absorption time, preventing occlusion and thrombosis, while maintaining effective drug delivery and biocompatibility, thereby addressing the limitations of existing stent coatings.

Implementation Method 1

The coating has an absorption period from about three months to about six months during which the coating is completely or substantially completely absorbed upon implantation in a human body

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentEP3130362B1An absorbable coating for implantable device
Publication Date: 2019.08.21 ABBOTT CARDIOVASCULAR SYSTEMS INC

AI summary

The present invention provides an absorbable coating for an implantable device and the methods of making and using the same.